A single arm, phase II study to determine the safety and efficacy of 4-HPRN-(4-Hydroxyphenyl) retinamide for treating oral intraepithelial neoplasia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenretinide (Primary)
- Indications Orofacial cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2012 Biomarkers information updated
- 23 Jul 2012 Actual end date (1 Mar 2000) added as reported by ClinicalTrials.gov.
- 17 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.